Indication: For treatment of opioid type drug dependence.
Pharmacology: Naltrexone, a pure opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. It markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids. When co-administered with morphine, on a chronic basis, Naltrexone blocks the physical dependence to morphine, heroin and other opioids. In subjects physically dependent on opioids, Naltrexone will precipitate withdrawal symptomatology.
Mechanism Of Action: Naltrexone binds to the opioid mu receptor antagonistically, thereby preventing conventional opiate (heroin, morphine) drugs from binding and inducing opioid neural responses. The mechanism of action of Naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids.
Drug Category: Anti-craving Agents; Depressants; Alcohol Antagonists; Opiate Antagonists; ATC:N07BB04
Interactions:
DrugBank: Interactions for Naltrexone
Interactions for Naltrexone:
Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed.
Consequently, caution is advised if the concomitant administration of REVIA and other drugs is required.
The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two
potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known
risks.
Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations,
antidiarrheal preparations, and opioid analgesics. In an emergency situation when opioid analgesia must be
administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting
respiratory depression may be deeper and more prolonged.
Chemical IUPAC Name: Not Available
Chemical Formula: C20H23NO4
Half Life: 4 hours
Drug Type: Approved Drug
# Accession No: APRD00005
CAS Registry Number: 16590-41-3
Naltrexone News (When available)
New rules for ACs kick in midwinterJan 6, 2006 Roanoke Times, Ron Revia is manager for Virginia Air Distributors' Roanoke branch, which is a wholesale distributor for York air conditioning and heat pump products in Roanoke ...
Sleeping Through Detox Poses HazardsJan 12, 2006 Psychiatric Times, ...abstinence, the anesthesia- and buprenorphine-assisted protocols were superior to the clonidine program in facilitating the naltrexone (ReVia) induction to ...
No. 8 Lawrence Co. girls hold off HazlewoodJan 12, 2006 The Decatur Daily, Sparks added 14 points and 20 rebounds. Also for Speake, Revia Brown scored 13 points, and Melea Hensley added nine points and eight rebounds. ...
Peanut butter, water may beat hangoverDec 27, 2005 Indianapolis Star, ...problem. They should talk with their doctor about medications (such as Antabuse, ReVia and Campral) that help people stop drinking. ...
Anecdotal evidence points to relief for MS sufferersJan 2, 2006 On Line opinion, The drug is Naltrexone (also known as ReVia) and my Health Success Stories database contains a growing body of compelling anecdotal evidence that it works, and ...
UPDATE 2-Long-acting alcoholism drug wins US supportDec 28, 2005 Reuters It is sold generically and under the brand name Revia by Barr Pharmaceuticals Inc. (BRL.N: Quote, Profile, Research) unit Duramed Pharmaceuticals Inc. ...
Long-acting alcoholism drug wins supportDec 28, 2005 Reuters.uk, ...pills. It is sold generically and under the brand name Revia by Barr Pharmaceuticals Inc. unit Duramed Pharmaceuticals Inc. Alkermes ...
Alford's bucket a winner for FalkvilleDec 27, 2005 The Decatur Daily, Whitney Sparks pitched in 11 points and 11 rebounds. Malea Hensley pulled down eight rebounds, and Revia Brown passed out five assists. ...
Lamar Institute of Technology fall graduatesDec 19, 2005 Beaumont Enterprise, Curtis Michael Kingston, Nederland; Jason Hunter Thigpen, Orange; Edward R. Lawler, Silsbee; Rodrick KiAndre Long, Tyler; Kristipher M. Revia, Tracy LeLeux ...
Long-acting alcoholism drug wins supportDec 28, 2005 Reuters.uk, Before final approval to sell the drug, formally called Vivitrex, Alkermes said it must still meet several conditions set by the Food and Drug Administration ...
Alkermes says alcoholism drug wins conditional OKDec 28, 2005 Reuters.uk, The drug, called Vivitrex, is an injectable form of naltrexone given once-a-month to help ward off a craving for alcohol. Cephalon Inc. ...
Conditional approval granted for alcoholism drugDec 28, 2005 Reuters.uk, Wednesday. The drug, called Vivitrex, is an injectable form of naltrexone given once a month to help ward off a craving for alcohol. ...
Cephalon's experimental alcoholism treatment progressesDec 28, 2005 Philadelphia Business Journal, Final approval of Vivitrol, formerly known as Vivitrex, is contingent upon finalizing the product label and the companies satisfying a request by the FDA for ...
FDA Clears Alkermes' Alcohol TreatmentDec 29, 2005 Smartmoney.com ...pharmacokinetic data. The new drug application for Vivitrol, formerly known as Vivitrex, was submitted on March 31. Alkermes and ...
FDA clears Alkermes alcoholism drugDec 29, 2005 United Press International ...alcohol dependence. The new drug application for Vivitrol -- originally named Vivitrex -- was filed with the FDA in March. Alkermes ...
Alkermes, Cephalon: FDA Calls Vivitrol ApprovableDec 29, 2005 BioWorld Online (subscription), ...and Cephalon Inc. have won marketing clearance for Vivitrol (formerly Vivitrex), their injectable drug against alcohol dependence. ...
Cephalon CEO readies for 4 new drug launchesDec 19, 2005 Reuters The FDA is due to rule on Vivitrex by December 30. Baldino said the jury is out on how effectively Vivitrex will perform over a lifetime of treatment. ...
Naltrexone Drug Wins Initial FDA ApprovalJan 3, 2006 JoinTogether.org Some market analysts said that annual sales of the drug could top $500 million. "We believe Vivitrex could become the gold standard for treatment of alcohol ...
Alcoholism Drug Still Awaits Final ApprovalDec 28, 2005 TheStreet.com Vivitrol, known as Vivitrex while it was being tested, is an injectable, extended-release version of naltrexone, a now-generic pill that's prescribed to ...
Alkermes alcoholism drug wins tentative OKDec 29, 2005 Boston Globe, ...has contact with alcohol. The drug was formerly called Vivitrex. The name was changed during the FDA review. Cephalon Inc., which ...
Cephalon Could See 2006 Sales Of $30M From VivitrolDec 29, 2005 Forbes Management of Cephalon and Alkermes said they plan to launch Vivitrol (formerly Vivitrex) in the second quarter of 2006, said Kulju, "a modest pushback" from ...
Approval of alcoholism drug gainsDec 29, 2005 International Herald Tribune, Alkermes hopes to turn Vivitrol, which was called Vivitrex before being changed during the FDA review, into the first widespread drug to treat alcoholism. ...
Alkermes Jumps On FDA Letter Regarding Vivitrol DrugDec 29, 2005 Business Online, Vivitrol, which the company had originally named Vivitrex, is believed to be an improvement on existing formulations of naltrexone because it need be ...
Business news in briefDec 20, 2005 Philadelphia Inquirer, ...year. Baldino said the biotechnology company also expected to sell Vivitrex, to treat alcoholism, with partner Alkermes Inc. in ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
